PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Care (Basel)
Autors principals: Hartkopf, Andreas D., Taran, Florin-Andrei, Wallwiener, Markus, Walter, Christina B., Krämer, Bernhard, Grischke, Eva-Maria, Brucker, Sara Y.
Format: Artigo
Idioma:Inglês
Publicat: S. Karger GmbH 2016
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290437/
https://ncbi.nlm.nih.gov/pubmed/28228704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000453569
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars